Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;5(5):474-5.
doi: 10.1093/ckj/sfs121.

Night blindness in a haemodialysed ADPKD patient receiving octreotide

Thien Anh Ho  1 , Pierre-Yves Decleire  2 , Jean-Jacques Lafontaine  2 , Yves Pirson  1
Affiliations

Night blindness in a haemodialysed ADPKD patient receiving octreotide

Thien Anh Ho et al. Clin Kidney J. 2012 Oct.
No abstract available

Keywords: ADPKD; octreotide; polycystic liver disease.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Non-enhanced abdominal computed tomography. Massive cystic enlargement of the liver, occupying a large part of the abdomen and responsible for severe abdominal distension. The left polycystic kidney is also visible.
See this image and copyright information in PMC

References

    1. Van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661–1668. - PubMed
    1. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21:1052–1061. - PMC - PubMed
    1. Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology. 2007;132:1104–1116. - PubMed
    1. Barbanoj M, Antonijoan R, Morte A, et al. Pharmacokinetics of the somatostatinanaloglanreotide in patients with severe chronic renal insufficiency. Clin Pharmacol Ther. 1999;66:485–491. - PubMed